Access to care and other health disparities result in the low use of novel therapies for Black, female and lower income type 2 diabetes patients. If these barriers aren't addressed, disparities among kidney and cardiovascular patients may worsen in the U.S.
In a recent study released by JAMA, it was found there’s a significance between race, gender, and socioeconomic status and the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors among patients with type 2 diabetes in the United States.
It was discovered in that in a study conducted from 2015 to 2019 of over 900,000 type 2 diabetes patients commercially insured and under Medicare Advantage, the use of SGLT2 inhibitors increased. However, the use remained low among patients with heart failure and kidney and cardiovascular disease. Black race, females and lower household income patients were associated with the lower inhibitor rates.
These results mean there are factors of social determinants of health (SDoH) present in SGLT2 treatment and if they aren’t addressed correctly, disparities among kidney and cardiovascular patients may worsen in the U.S.
This is an issue because SGLT2 inhibitors significantly reduce deaths from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney disease among patients with type 2 diabetes. According to the study, Black individuals have an unreasonable burden of cardiovascular and chronic kidney disease; all while adoption of novel therapeutics for this group, for female, and low socioeconomic status patients have been slower compared to White, male, or higher economic status patients.
Of patients 18 and older, 8.7% of those recorded in the study received inhibitor treatment during that time period while 91.3% did not.
Patients - typically Black, female and of low-income households – were shown to have these limitations to this novel treatment due to a number of barriers. These barriers include decreased access to quality diabetes care and to specialists familiar with the benefits of SGLT2 inhibitor use, structural racism, provider bias that certain groups of patients may be less likely to be adherent to treatment with an expensive agent, and prescription abandonment owing to economic barriers, according to the study.
Additionally, it’s been found in prior studies lower rates of SGLT2 inhibitor prescription continued even after adjustment for visits to cardiology and endocrinology specialists. This result suggests that racism and bias in care delivery may contribute to the findings of this study as well.
Given the increasing amount of evidence supporting the clinical benefit of SGLT2 inhibitor treatment, further investigation of barriers to accessing this therapy and the implementation of strategies to address racism and ensure more equitable use of this therapy among Black patients are essential.
Data in the study for inequities toward Latinx patients were not present in SGLT2 inhibitor use, however, Asian race was associated with a lower rate of SGLT2 inhibitor use. Although, for Asian patients who have access to care, provider interactions are more frequently characterized by lower rates of patient-centered care and input regarding treatment decisions, which may explain the results.
Gender Inequalities
In addition to racial inequities in SGLT2 inhibitor use, other structural inequities were discovered based on gender and socioeconomic status. Among patients with type 2 diabetes, females were less likely to be prescribed an SGLT2 inhibitor, even among those with heart failure, cardiovascular and kidney disease. This is consistent with findings from prior studies of female patients in where therapies were initially adopted more slowly and underused among female patients. Poor provider communication may also contribute to gender inequity.
Socioeconomic Status Inequalities
Those with a median household income of greater than or equal to $100,000 were 8% more likely and those with a median income ranging from $50,000 to $99,999 were 5% more likely to receive SGLT2 inhibitor therapy than were those with a median income of less than $50,000.
Affordability and out-of-pocket costs of these agents may be excessive, leading to prescription abandonment, especially compared with the cost of older, more traditionally used therapies. Despite SGLT2 inhibitor coverage being relatively high in 2019 for Medicare beneficiaries, median retail prices for a 30-day supply were $300. Estimated annual out-of-pocket costs ranged from $1,097 to $1,211.
Commercial insurance was one of the factors most strongly associated with SGLT2 inhibitor prescription in the study, suggesting sufficient coverage and medication cost may be associated with different rates of use. Given the cost- effectiveness of these medications, the results suggest out-of-pocket costs should be minimized. In addition, provider biases about the ability of patients with lower socioeconomic status to afford and adhere to treatment with an SGLT2 inhibitor may contribute to differential prescribing patterns.
Lastly, it was found in the study having a visit with an endocrinologist in the past 12 months was one of the strongest factors positively associated with SGLT2 inhibitor use. The demonstrated clinical benefit may not yet be common knowledge among many providers who treat patients with diabetes. Strategies to increase the comfort of all providers with prescribing SGLT2 inhibitor therapy will be essential to address inequitable use and ensure improved cardiovascular and kidney outcomes for all patients with type 2 diabetes.
Lack of Diversity in Clinical Trials Hurts Research, and Costs Billions | AHA Scientific Sessions
November 12th 2023Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
Can Medical Schools Help Improve Outcomes for Minorities Living with Diabetes?
July 21st 2023Professional development should take steps to incorporate outreach into medical school curriculums, say Rosemay Michel, D.P.M., and Gary M. Rothenberg, D.P.M. "Students must learn what motivates people to make healthy choices in their daily lives, including the influences of schools, faith-based groups, social media and extended family on personal decision-making," argue Michel and Rothenberg.
Read More
Lilly Slashed Its Insulin Prices. Will Sanofi and Novo Nordisk Do the Same?
March 2nd 2023Patient groups and lawmakers such as Sen. Bernie Sanders want Sanofi and Novo Nordisk to follow Eli Lilly's example and reduce the prices of their insulin products. Both companies said they already have programs that bring down the cost.
Read More
Some Mental Health Conditions Add to the Atrial Fibrillation Risk from Diabetes, Study Finds
December 9th 2022Korean study shows that depression, insomnia and anxiety add to the risk of atrial fibrillation among those with diabetes, according to a Korean study. Those mental health condition may affect the autonomic nervous system that regulates the heart. Bipolar disorder and schizophrenia did not increase the risk.
Read More